Literature DB >> 4009196

Levodopa and melanoma: three cases and review of literature.

F H Rampen.   

Abstract

Three patients are reported who developed a melanoma while taking levodopa for Parkinson's disease. There were two cutaneous melanomas and one metastatic melanoma with occult primary. The literature on the association of Parkinson's disease, levodopa therapy and melanoma is reviewed. The capacity of levodopa to induce melanomas and its alleged adverse effect on the clinical course of the disease are questioned.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4009196      PMCID: PMC1028378          DOI: 10.1136/jnnp.48.6.585

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  13 in total

1.  L-dopa: selective toxicity for melanoma cells in vitro.

Authors:  M M Wick; L Byers; E Frei
Journal:  Science       Date:  1977-07-29       Impact factor: 47.728

2.  Levodopa and melanoma.

Authors:  A N Lieberman; J L Shupack
Journal:  Neurology       Date:  1974-04       Impact factor: 9.910

3.  Levodopa and malignant melanoma.

Authors:  E Robinson; J Wajsbort; B Hirshowitz
Journal:  Arch Pathol       Date:  1973-03

4.  Multiple primary melanoma following administration of levodopa.

Authors:  J L Skibba; J Pinckley; E F Gilbert; R O Johnson
Journal:  Arch Pathol       Date:  1972-06

5.  Levodopa and melanoma.

Authors:  J Fermaglich; P Delaney
Journal:  JAMA       Date:  1979-03-02       Impact factor: 56.272

6.  [Connection between levodopa therapy and malignant tumors].

Authors:  A Botteri; P O Nordström
Journal:  Lakartidningen       Date:  1979-01-31

7.  Parkinson's disease, melanoma, and levodopa.

Authors:  J Fermaglich; P Delaney
Journal:  J Neurol       Date:  1977-06-13       Impact factor: 4.849

8.  Levodopa therapy and malignant melanoma.

Authors:  A J Sober; M M Wick
Journal:  JAMA       Date:  1978-08-11       Impact factor: 56.272

9.  Epidermotropically metastatic malignant melanoma. Differentiating malignant melanoma metastatic to the epidermis from malignant melanoma primary in the epidermis.

Authors:  R Kornberg; M Harris; A B Ackerman
Journal:  Arch Dermatol       Date:  1978-01

10.  Levodopa administration and multiple primary cutaneous melanomas.

Authors:  J E Bernstein; M Medenica; K Soltani; A Solomon; A L Lorincz
Journal:  Arch Dermatol       Date:  1980-09
View more
  3 in total

1.  High prevalence of malignant melanoma in Israeli patients with Parkinson's disease.

Authors:  R Inzelberg; J M Rabey; E Melamed; R Djaldetti; A Reches; S Badarny; S Hassin-Baer; O Cohen; H Trau; J Aharon-Peretz; R Milo; M Schwartz; M Huberman; L Gilead; M Barchana; I Liphshiz; C Fitzer-Attas; N Giladi
Journal:  J Neural Transm (Vienna)       Date:  2011-02-05       Impact factor: 3.575

Review 2.  The particular relationship between Parkinson's disease and malignancy: a focus on skin cancers.

Authors:  Rivka Inzelberg; Simon D Israeli-Korn
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

3.  Lid melanoma and parkinsonism.

Authors:  S A Haider; V T Thaller
Journal:  Br J Ophthalmol       Date:  1992-04       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.